Sherpa Healthcare Partners is a venture capital firm established in 2018 and based in Beijing, China. The firm specializes in investing in the pharmaceutical and biotechnology sectors, with a focus on life technology, medical devices, diagnostics, and medical services. Sherpa Healthcare Partners seeks to identify and cultivate sector leaders and innovators, leveraging its expertise to build a strong portfolio of investments. Through strategic collaborations and relationships, the firm aims to create lasting value and support advancements in healthcare technology and services.
Kunwei Technology manufactures high-precision force sensors (six-axis force sensors) as well as force control systems. It is involved in the research and development, manufacturing, sales, and technological promotion of intelligent force sensors, as well as the development of force sensor products for the robot and other intelligent equipment industries. It provides force measurement systems as well as goods connected to measurement and other industries.
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.
ZWI Therapeutics is a biotechnology company focused on enhancing the efficacy and safety of protein therapeutics. The company is developing an advanced polymer designed to reduce immunogenicity and improve pharmacokinetics, facilitating the creation of nanoparticles and hydrogels for therapeutic use. Utilizing machine learning, ZWI Therapeutics aims to identify and develop immunotherapies that minimize immune responses, paving the way for new treatments for cancer, autoimmune diseases, and various other conditions. Through its innovative approach, ZWI Therapeutics seeks to provide patients with effective and safe treatment options.
Astra Space, Inc. is a technology company based in Alameda, California, that specializes in designing and building rockets for satellite delivery and launch services. Founded in 2004 and originally known as Ventions LLC, the company rebranded in 2016 and aims to provide accessible and affordable access to space. Astra offers online reservations for payload deliveries to both sun-synchronous and low inclination orbits, with a focus on dedicated launch services for payloads ranging from 50 kg to 150 kg. The business is divided into two segments: Launch Services, which provides rapid global launch capabilities, and Space Products, which includes the development of space products tailored to customer needs for successful satellite launches. Astra operates test facilities to support its operations and is committed to facilitating frequent access to space for satellite operators and governments.
Lifeshield Medical focuses on life support systems. The current products include a new generation of in vivo interventional cardiac support systems, extracorporeal carbon dioxide removal systems (ECCO2R) for the treatment of severe COPD and ECMO extracorporeal membrane oxygenation systems. The company is actively cooperating with domestic clinicians and continues to develop and industrialize several innovative life support system products and solutions such as heart, brain, lung, liver, and kidney to meet the clinical needs of the Chinese and EU markets and serve more patients.
GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.
Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.
BlissBio is a biopharmaceutical company dedicated to the development of innovative therapies for cancer treatment. The company specializes in tumor targeting and immunotherapy, focusing on the creation of antibody-drug conjugates and site-specific conjugate technologies. With a robust pipeline of products, BlissBio possesses independent intellectual property rights that support the advancement and commercialization of its anti-tumor therapies, aiming to provide effective solutions for patients battling cancer.
Huihe Healthcare
Series C in 2022
Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.
ClinChoice Kunling was established in Tianjin inSince its establishment, through its own organic growth and strategic mergers and acquisitions, ClinChoice has more than 3,000 clinical R&D professionals around the world, located in hot cities and regions of domestic and foreign pharmaceutical R&D, and has developed into a local clinical CRO enterprise model supporting innovative drug device R&D. . The company adheres to the connotation of "Kunxing Zhiyuan · Ling creates the future", which means to become an ideal partner for the clinical research and development of innovative pharmaceutical devices.
Developer of edible microbial synthetic protein food intended to provide new form of protein sources. The company focuses on the research, development and industrialization of new microbial proteins and biosynthetic proteins, enabling clients with safe, nutritious and delicious microbial substitute protein artificial food, while lowering carbon emissions.
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.
Raykol is a national high-tech enterprise in China specializing in automated and intelligent laboratory solutions aimed at enhancing the efficiency of the inspection and testing industry. The company focuses on three primary sectors: food safety, environmental protection, and life sciences. It offers a comprehensive range of services including R&D, production, sales, and third-party testing. Raykol's expertise stems from its development of automated stand-alone modules, machine vision, and motion control technology, enabling the creation of fully integrated workstations for laboratory automation. Additionally, the company operates a service and training center that provides after-sales support, training, demonstration, analysis outsourcing, method development, and project cooperation, ensuring customers receive complete one-stop solution services.
Starna Therapeutics is focused on developing innovative drugs that utilize RNA technology at their core. The company possesses a proprietary RNA and organ-selective delivery technology platform, which underpins its extensive research and development pipeline. This pipeline addresses unmet clinical needs in various areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its independent intellectual property rights, Starna Therapeutics aims to advance the field of RNA-based therapeutics and contribute to significant advancements in healthcare.
HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.
Cataya Bio (Shanghai) Co., Ltd. is focused on developing synthetic biological products for diverse industries through its advanced engineering biology platform and biomanufacturing capabilities. The company engineers microbes and creates clean fermentation processes to produce high-purity products sustainably and cost-effectively. By leveraging synthetic biology technology, Cataya Bio enables clients to obtain natural and sustainable raw materials, contributing to a shift away from petroleum-based resources. The company's efforts address critical global challenges such as environmental preservation, carbon emissions, and climate change.
Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.
UniXell
Seed Round in 2022
UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.
UniXell Biotechnology is a developer of cell therapies utilizing human pluripotent stem cell technology. The company focuses on addressing unmet medical needs in neurodegenerative diseases, rare diseases, and tumors. UniXell has established multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology, and high-precision gene editing. These innovations enable the development of effective treatment solutions aimed at improving the lives of patients suffering from complex medical conditions. The company's proprietary intellectual property encompasses various aspects of stem cell preparation, cultivation, differentiation, and gene editing, positioning it as a leader in the advancement of cellular therapies.
Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
MindRank is an artificial intelligence (AI)-driven drug discovery company focused on streamlining the drug development process. Utilizing its proprietary AI platforms, including PharmKG, Molecule Dance, and Molecule Pro, the company aims to expedite the creation of small molecule medicines that offer unique benefits and improved clinical outcomes. MindRank's technology efficiently recommends cost-effective synthesis routes for various compounds and supports drug design, enabling clients to develop effective pharmaceuticals more quickly and efficiently. Through its innovative approach, MindRank seeks to transform the landscape of drug discovery.
Starna Therapeutics is focused on developing innovative drugs that utilize RNA technology at their core. The company possesses a proprietary RNA and organ-selective delivery technology platform, which underpins its extensive research and development pipeline. This pipeline addresses unmet clinical needs in various areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its independent intellectual property rights, Starna Therapeutics aims to advance the field of RNA-based therapeutics and contribute to significant advancements in healthcare.
Fuse Biotherapeutics is a biotech company developing next-generation immune-modulating therapeutics for patients with cancers. The company's therapeutic approach integrates the multiple steps of an immune response in a rational manner such that potent responses to danger are targeted without sacrificing natural breaks in the system that spare healthy tissues. Fuse Biotherapeutics was founded in 2021 and is headquartered in Los Angeles, CA.
Sepax Technologies is a biotechnology firm specializing in chromatography products aimed at the separation and purification of pharmaceuticals and biologics. The company provides a diverse range of offerings, including liquid chromatography columns, bulk resins, and systems that cater to various modalities such as size exclusion chromatography, ion exchange, hydrophobic interaction chromatography, affinity chromatography, and reversed-phase chromatography. These products are designed to assist biological researchers and scientists in achieving high-resolution, high-efficiency, and high-recovery separations of proteins, oligonucleotides, peptides, and other biomolecules. Additionally, Sepax Technologies offers method development services to further support its clients in their research endeavors.
Wuxi Biortus Biosciences Co. Ltd. is a contract research organization based in Jiangyin, China, specializing in research and development services that support drug discovery. Founded in 2009, the company offers a range of services, including recombinant protein production, in vitro assays and screening, medicinal chemistry, structural biology, and target validation. Wuxi Biortus Biosciences is recognized for its commitment to quality and innovation, having established five advanced research platforms that enhance its capabilities in drug development. The company’s R&D team has developed various innovative techniques, some of which have been patented, further solidifying its role in the biotechnology sector. It operates as a subsidiary of Jiangsu Shuangliang Group Company Ltd.
Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.
CashBackApp helps fast-moving consumer goods (FMCG) companies create customer loyalty by allowing them to earn cashback via M-Pesa on their routine purchases.
Krinwave is an ultrasound imaging equipment company. Kunwei Technology's original kOS imaging platform achieves the perfect combination of ultra-high penetration and deep resolution for the first time in the industry, resulting in deep super-resolution images.
Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective solutions. Bota Biosciences has created an integrative bioengineering platform that connects biological design to scale-up manufacturing, facilitating the transition to sustainable living. It operates its own pilot plant and manufacturing facility, which enhances its capacity to offer scalable industrial solutions and market-ready products across various sectors, including nutrition, food, personal care, and animal health. With a dynamic and multidisciplinary team, Bota Biosciences aims to channel biotechnology innovations for a global impact. The company has successfully raised substantial funding, exceeding $145 million, with investments from several prominent strategic and financial backers.
Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
MAXVAX is focused on the development and commercialization of innovative vaccines, specifically targeting viral diseases such as rotavirus, shingles, and herpes. The company's technology is designed to enhance treatment options within the biotechnology industry, enabling healthcare professionals to offer improved solutions for patients suffering from these infections. By concentrating on effective vaccine development, MAXVAX aims to contribute significantly to the healthcare sector and improve patient outcomes.
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
XISOFT is a professional manufacturer specializing in informatization and data services within health economic management. The company develops an enterprise resource planning (ERP) platform tailored for hospitals, providing comprehensive management and monitoring capabilities across various functions, including finance, supply chain, human resources, and diagnosis-related groups. By leveraging technology, XISOFT aims to support medical institutions in streamlining operations and enhancing efficiency. Its platform enables effective business integration and refined management, addressing key areas such as intelligent finance, material assets, internal control, and event management. Through its innovative solutions, XISOFT assists healthcare providers in realizing their strategic objectives and improving overall operational effectiveness.
MindRank is an artificial intelligence (AI)-driven drug discovery company focused on streamlining the drug development process. Utilizing its proprietary AI platforms, including PharmKG, Molecule Dance, and Molecule Pro, the company aims to expedite the creation of small molecule medicines that offer unique benefits and improved clinical outcomes. MindRank's technology efficiently recommends cost-effective synthesis routes for various compounds and supports drug design, enabling clients to develop effective pharmaceuticals more quickly and efficiently. Through its innovative approach, MindRank seeks to transform the landscape of drug discovery.
Appia Bio is a biotechnology company dedicated to the research and development of allogeneic cell therapies that can be readily available for patients. The company focuses on creating engineered cell therapies for various medical conditions using its innovative ACUA technology platform. This platform utilizes the biology of lymphocyte development along with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to produce CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes derived from hematopoietic stem cells. By maturing and scaling healthy stem cells into these therapies, Appia Bio aims to provide safe and targeted cancer treatments, thereby enhancing accessibility to off-the-shelf cell therapies for physicians and patients alike.
Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.
Brattea is a medical device research and development company. Brattea focuses on the development and commercialization of renal denervation products with indications in hypertension, cancer pain and diabetes.
EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform. Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.
Visen Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for endocrine diseases. The company is dedicated to addressing significant unmet medical needs in this field, particularly within the Chinese market, and aims to provide both first-in-class and best-in-class treatment solutions for patients of all ages, including those with rare endocrine conditions. With a commitment to patient-centric care, Visen strives to improve treatment outcomes and quality of life for individuals affected by these diseases. The company is backed by a team of experienced professionals with extensive backgrounds in the pharmaceutical industry and operates offices in major Chinese cities such as Shanghai, Beijing, Hong Kong, and Taipei. To further enhance its research, development, and manufacturing capabilities, Visen has established a Greater China research and development site in Suzhou, aiming to deliver advanced treatment options to Chinese patients more effectively.
CotheraBio develops innovative cancer therapies with a focus on translational oncology. It has developed its proprietary i-CR® technology platform, which is a powerful method for providing individualized drug screening and new drug development. The platform combines a high content screening system with the conditional reprogramming of primary cultured tumor cells, which enables the efficient and undifferentiated expansion of primary patient-derived tumor cells in vitro, while also preserving the tumor’s heterogeneity.
Shanhu Health focuses on the development of clinical application software within the realm of digital medicine. The company creates computerized systems aimed at enhancing clinical research, including interactive response technology, electronic data capture, and clinical trial management systems, all utilizing cloud technology. Additionally, Shanhu Health offers consultancy services that support risk-based monitoring and the implementation of clinical trial systems, thereby facilitating more efficient drug development processes.
Vazyme Biotech is devoted to the development and production of enzymes and antibodies. Our products cover clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research and other related fields. The company is located in the city of Nanjing, china's ancient capital of the Six Dynasties. Vazyme Biotech is in the front of scenic Qixia mountain, dependent on the regional radiation force of the National Economic and Technological Development Zone of Nanjing. With advanced capability of R&D and cutting- edge technology, Vazyme Biotech will create a new pattern of National Biotechnology.
Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective solutions. Bota Biosciences has created an integrative bioengineering platform that connects biological design to scale-up manufacturing, facilitating the transition to sustainable living. It operates its own pilot plant and manufacturing facility, which enhances its capacity to offer scalable industrial solutions and market-ready products across various sectors, including nutrition, food, personal care, and animal health. With a dynamic and multidisciplinary team, Bota Biosciences aims to channel biotechnology innovations for a global impact. The company has successfully raised substantial funding, exceeding $145 million, with investments from several prominent strategic and financial backers.
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.
Belief Biomed
Venture Round in 2020
Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.
Nanovision Technology is located in Zhongguancun Yongfeng high-tech industrial base, with thousands of square meters of R&D foundation in Yonyou Industrial Park. We also set up a subsidiary company in Chengdu. their company is a high-tech enterprise focused on high-speed and high-precision radiology imaging.Nanovison focus in static CT，x-ray CMOS detectors and x-ray imaging software, etc.Which can be widely used in medical, industrial, security and other fields.
HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.
Guoke Hengtai (Beijing) Medical Technology Co., Ltd., established in February 2013, is a company based in the Yizhuang Economic and Technological Development Zone of Beijing. It operates under the umbrella of Oriental Science and Technology Holding Group Co., Ltd., a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. The company specializes in the distribution and direct sales of medical devices, offering a range of professional services, including warehousing logistics, distribution channel management, and hospital SPD operation management. Since its inception, Guoke Hengtai has experienced significant growth, achieving a compound annual growth rate exceeding 50% over four years and embarking on an initial public offering journey in 2017.
Joinhealth Technology is an artificial intelligence patient management company that provides medical health information and medical health services. It is based on the "Ji Shi Brain" and combines the mainstream technology such as Internet + Internet of Things to utilize the accumulation and precipitation of massive knowledge bases. The treatment of diseases has changed to disease management, and the closed-loop intelligent management of patients from the hospital to the home to the re-admission has been realized.
EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform. Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.
Leto Laboratories focuses on research and development in the field of protein re-engineering, aiming to address gaps in the treatment of cancer and rare diseases. The company employs advanced technologies, including high-throughput protein re-screening, purification, and drug formulation development platforms. By leveraging these innovative approaches, Leto Laboratories strives to create more effective protein-based therapies, enhancing treatment options for patients. The diverse research team works collaboratively to advance the company's mission of improving healthcare outcomes through specialized protein technology.
Yosemite Clinic is a full-service clinic providing convenient walk-in medical services in a state-of-the-art environment in Central Pudong. They offer family medicine, internal medicine, surgery, orthopedics (sports medicine), dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, anesthesiology, rehabilitation medicine, medical imaging, laboratory, pharmacy and more. Their onsite facilities and equipment include CT, X-ray, Ultrasound, Laboratory and Operating Rooms. Their doctors come from China and across the world, enabling us to serve you in many languages including, English, Japanese, Malay, Mandarin Chinese and Cantonese.
ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.
Hexaell Biotechnology Co., Ltd is a start-up specializing in stem cell technology and artificial organs, focusing on innovative solutions for severe liver diseases. The company has licensed advanced technologies for developing bio-artificial livers that aim to replace human liver function and treat liver failure. Hexaell's research is based on findings published in prominent scientific journals, and it has conducted pilot clinical studies involving six liver failure patients at leading hepatopathy centers in China. By employing cell differentiation and production techniques, Hexaell is committed to providing effective treatment options for those suffering from liver conditions.
Wag is a mobile application used to instantly find trusted and certified dog walkers. You’ll receive a push notification when the walk starts, followed by real-time GPS tracking of the walk. Once the walk is complete, you’ll receive a report card with a photo, notes, the distance traveled, and a pee/poop report.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.